Background: Triple-negative breast cancer (TNBC) is an aggressive disease, nevertheless exhibiting a high response rate to chemotherapy. Since the retinoblastoma protein (pRb) loss confers a high sensitivity to chemotherapy regimens, we evaluated the prevalence of pRb loss in TNBCs and its relevance on the clinical outcome of patients treated with adjuvant chemotherapy.
introduction
Human breast carcinomas constitute a heterogeneous group of tumors which are characterized by different clinical behaviors and responses to treatments. Gene expression profiling studies have shown that this heterogeneity is related to different biological features which are specific for the various cancer subtypes [1] [2] [3] [4] [5] [6] . Among these subtypes, the triple-negative breast cancer (TNBC) group, constituted by cancers which do not express estrogen receptor (ER), progesterone receptor (PR) or human epidermal growth factor receptor 2 (HER2), accounts for 10%-17% of all breast carcinomas [7] . Due to the absence of hormone receptors and HER2 expression, these tumors cannot take advantage from the endocrine therapy or trastuzumab treatment, chemotherapy remaining the only potential adjuvant therapeutic approach. As far as sensitivity to chemotherapy is concerned, the TNBCs exhibit higher rates of objective response to neoadjuvant chemotherapy than other tumor types (reviewed in 7), thus suggesting that biological features present more frequently in this group are responsible for the increased sensitivity to chemotherapy. We have recently shown that adjuvant chemotherapy is much more effective in human breast cancers lacking retinoblastoma protein (pRb) expression than in those expressing the tumor suppressor protein. In fact, chemotherapy significantly extended diseasefree survival (DFS) in patients whose cancers lacked pRb compared with patients whose cancers expressed the tumor suppressor protein [8] . Therefore, in the present study, we carried out an immunohistochemical analysis on a large consecutive series of primary breast cancers and evaluated the prevalence of pRb loss in triple-negative tumors in comparison to those pertaining to the nontriple-negative group. We found that pRb loss preferentially occurred in the triple-negative cancers with respect to other cancer types. We thus investigated whether this difference in pRb expression was related to the original article clinical outcome of patients with TNBCs treated with adjuvant chemotherapy. We observed that patients with cancers lacking pRb expression were all free of the disease at a medium follow-up time of 109 months.
patients and methods patients A total of 518 consecutive patients were studied, all of whom underwent surgical resection for primary invasive breast carcinoma at the Surgical Department of the University of Bologna from 1991 to 1995. Details of the entire female cohort have been published elsewhere [8] . The main clinical and histopathological characteristics of the studied population are summarized in Table 1 . The present study was approved by the Senior Staff Committee, the board which was responsible for regulating noninterventional studies at the time of patient enrolment. This board is equivalent to an Institutional Review Board.
adjuvant treatments
In all, 145 patients received six cycles of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) chemotherapy. The dose of cyclophosphamide and 5-fluorouracil (5-FU) was 600 mg/m 2 of body surface area, and the dose of methotrexate (MTX) was 40 mg/m 2 . In all, 231 patients received adjuvant endocrine therapy alone (tamoxifen, 20 mg daily, for at least 2 years). A total of 41 patients received radiotherapy only and 93 patients did not receive any kind of adjuvant therapy. Patients were regularly followed up every 6 months for a median observation time of 109 months (range 4-142 months).
immunohistochemical assessment
Tissue sections were processed for immunohistochemistry using the following mAbs: anti-p53 mAb (clone BP53-12.1), anti-Ki67 (clone MIB-1), anti-HER2 internal domain (clone CB11), anti-ER (clone 1D5) and anti-PR (clone 1A6), all from BioGenex Laboratories (San Ramon, CA). RB protein immunostaining was assessed using two different mAbs: clone G3-245 (BioGenex Laboratories), which specifically recognizes the phosphorylated pRb form, and clone 1F8/Rb1 (Neomarkers, Lab Vision), which identifies all forms of pRb (phosphorylated as well as unphosphorylated or underphosphorylated). All mAbs were applied overnight at room temperature at the predetermined optimal concentrations. Nuclear immunostaining of ER, PR, Ki67, p53 and RB was assessed by image cytometry using the Cytometrica program (C&V), as previously detailed [9] . Staining was expressed as the percentage of labeled nuclear area over the total neoplastic nuclear area in the section [labeling index (LI)]. For each case, at least 2000 cells were evaluated. HER2 membrane immunostaining pattern and intensity were assessed by direct microscope evaluation following the four-class scoring system (0, +1, +2, +3) according to the published protocols [10] . All immunohistochemical analyses were carried out at the time of diagnosis.
immunohistochemical definition of TNBCs and other tumor subtypes
There is evidence that tumor subtypes, as defined by gene expression analysis, can also be identified by immunohistochemical markers [11] [12] [13] . In the present study, four immunohistochemical profiles were defined, according to the expressions of ER, PR and HER2: the triple-negative subtype, which lacks ER, PR and HER2, the ER2, PR2 and HER2+ subtype, the luminal A (ER+ and/or PR+ and HER22) and the luminal B (ER+ and/or PR+ and HER2+) subtypes. We considered cancers with a percentage of stained cells >10 to be ER and PR positive. Regarding HER2 expression, cases were classified as negative (classes 0 and +1), and positive (classes +2 and +3).
immunohistochemical definition of pRb status in tumor samples
In the present study, we first assessed the pRb phosphorylation level by evaluating the phospho-pRb LI in all the tumors taken into account. In our series, 40 cases (7.7%) showed very low positivity for phosphorylated pRb 
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(LI < 1%): therefore, these cases were assumed to include two kinds of tumors: (i) tumors in which pRb was present but only phosphorylated in a few cells and (ii) tumors in which both pRb forms were absent, most likely due to RB1 deletion. To differentiate between these two groups, the 40 cases were analyzed for the presence of total pRb, using a specific mAb that recognizes both the phosphorylated and the unphosphorylated or underphosphorylated pRb forms. In all, 31 cases showed no immunostaining in the cancer cell population. These cases were definitively regarded as pRb lacking.
statistical analysis
Differences among categorical variables were evaluated using the v 2 test.
DFS rates were calculated according to the Kaplan-Meier method, and the log-rank test was used for comparison of DFS curves. All statistics were carried out using the SPSS statistical software package (Statistical Package for Social Science, SPSS Inc., Chicago, IL). Values for P <0.05 were regarded as statistically significant.
results
In our breast cancer series, we identified 53 tumors as triplenegative cancers, corresponding to 10.2% of the 518 cases taken into account. This value was within the range (10%-17%) reported for the frequency of triple-negative cancers among all breast cancers [7] . According to the expression of hormone receptors and HER2, we also identified 61 cases pertaining to the ER2, PR2 and HER2+ subtypes, 284 cases to luminal A (ER+ and/or PR+ and HER22) and 120 cases to luminal B (ER+ and/ or PR+ and HER2+) subtypes. Table 1 shows the characteristics of patients with the triple negative cancer subtype compared with those of patients with other cancer subtypes gathered together in one group (the nontriple-negative group).
patients clinical outcome
In Figure 1 , the clinical outcome of the four subtypes of tumors is reported (univariate DFS analysis), independently of the adjuvant treatment. After a mean follow-up time of 109 months, the best prognosis was associated with the luminal A type, followed by the triple-negative tumors, whereas a poor clinical outcome was associated with both the luminal B and ER2/PR2/HER2+ subtypes. Therefore, in our series, triplenegative tumors did not appear to be characterized by a more aggressive clinical behavior compared with other types of breast cancer. According to the previous results [14] , we found that in patients with triple-negative tumors, adverse events were concentrated in the first 40 months after surgery, whereas in other tumor subtypes they were distributed throughout the entire follow-up period. We also analyzed the clinical outcome of patients according to their adjuvant therapy treatment. Chemotherapy-treated patients with triple-negative tumors maintained an optimal prognosis in comparison to those affected by other tumor subtypes (Table 2 ). This was not true for patients with triple-negative tumors subjected to hormone treatment, as they were characterized by a poorer clinical outcome in comparison to patients with luminal A cancer.
RB status and the clinical outcome of chemotherapy-treated patients with triple-negative tumors
Immunohistochemical analysis of the pRb status was carried out using anti-RB mAbs recognizing either the phosphorylated pRb form or both the phosphorylated and the unphosphorylated or underphosphorylated pRb forms. Tumors which were not stained by either mAb were considered pRb deficient. Regarding the level of pRb phosphorylation, the phosphorylated-pRb LI variable was dichotomized using the cut-off point of 25%, according to Derenzini et al. [15] , thus obtaining two groups of tumors: we considered one as normally phosphorylated (phosphorylated-pRb LI < 25) and the other as hyperphosphorylated (phosphorylated-pRb LI ‡25). The distribution of the three forms of pRb within breast cancer subtypes is shown in Table 3 . The percentage of tumors without pRb expression was significantly higher in the triple-negative subtype (64.5%) than in ER2/PR2/HER2+ tumors (22.6%) (P = 0.001), luminal A (6.5%) (P < 0.001) and B tumors (6.5%) (P < 0.001). The latter two types of tumors appeared to be characterized mainly by a normal pRb status, whereas the higher percentage of hyperphosphorylated-pRb cases was found in the ER2/PR2/HER2+ subtype. It is worth noting that 37.7% of TNBCs were pRb deficient compared with only 2.3 % of other cancer types (P < 0.001). In Figure 2 , the clinical outcome of patients with triple-negative tumors submitted to chemotherapy is reported, according to the presence or absence of pRb expression. All patients with pRb loss were found to be disease free, whereas those with normal or hyperphosphorylated-pRb had a significantly poorer prognosis. The opposite situation was recorded for patients submitted to hormone treatment: patients with pRb loss were shown to have a worse clinical outcome than those with normal or hyperphosphorylated-pRb [8] . The results reported above indicated that the lack of pRb expression represented a strong predictive parameter of DFS in TNBC patients who received chemotherapy. There is evidence that TNBCs are characterized by a high aggressive phenotype. Therefore, we have considered the possibility that the highly favorable clinical outcome of chemotherapy-treated patients might be related to other anatomo-clinical parameters associated with an aggressive phenotype that can confound the results of the statistical analysis. For this reason, we analyzed the prognostic relevance of the node status, tumor original article Annals of Oncology size, histological grade, Ki67-and p53-LI which are wellestablished tumor-related factors which might also influence the clinical outcome of the patients treated with adjuvant therapy [16, 17] . The predictive value relative to these variables and to pRb status is reported in Table 4 . None of these variables, with the exception or pRb status, resulted to be significantly associated with the clinical outcome. Interestingly, 22 of 24 TNBCs were of high histological grade and high Ki67-LI, thus excluding the possibility to perform a multivariate analysis of DFS including these variables.
discussion
The results of the present study indicate that TNBCs are characterized by a more frequent loss of pRb expression than other types of breast cancers. Furthermore, among the patients who received chemotherapy, those whose cancers lacked pRb had a much better prognosis than those whose cancers expressed the tumor suppressor protein, with all the former patients being free of the disease at the last follow up.
TNBCs are characterized by higher rates of objective pathological response to neoadjuvant anthracycline plus taxane neoadjuvant chemotherapy [13] compared with other molecular subgroups. However, long-term follow-up analysis has shown that the clinical outcome of these patients is not very different from that of patients with other types of cancer [14] . This was explained by the fact that patients with triple-negative cancer who were not responsive to the adjuvant or neoadjuvant chemotherapy had a significantly poorer prognosis than those with tumors pertaining to other subgroups [13, 18] . Triple-negative cancers therefore seem to harbor a biological feature that, when present, makes them highly sensitive to chemotherapy. In the absence of this specific feature, the highly aggressive phenotype of these cancers would determine the poor clinical outcome for patients. The present results suggest that the loss of pRb expression is this biological feature.
high incidence of pRb loss in triple-negative tumors
In the present study, we evaluated the prevalence of pRb loss by immunocytochemistry on the four breast cancer subtypes, defined by the expression of the hormone receptors and HER2. We found that 64.5% of pRb-deficient tumors were triple-negative cases and that 37.7% of triple-negative tumors were pRb deficient compared with 2.3% of other cancer types. Regarding pRb inactivation by hyperphosphorylation, the percentage of TNBCs with hyperphosphorylated pRb was not significantly different to that of other cancer subtypes, thus indicating that pRb loss, but not pRb functional inactivation by hyperphosphorylation, represented a frequent biological characteristic of triplenegative tumors. DFS, disease-free survival; ER2, estrogen receptor; PR2, progesterone receptor; HER2+, human epidermal growth factor receptor 2. Annals of Oncology original article the loss of pRb expression is associated with a favorable clinical outcome of chemotherapytreated patients with triple-negative tumors RB is a major tumor suppressor protein which negatively controls cell cycle progression [19] . The inactivation of the RB tumor suppressor pathways is associated with tumor genesis and characterizes a large fraction of many types of cancers [20, 21] . The RB protein interacts with a family of transcriptional regulators termed E2Fs, which control the expression of those genes whose products are important for both the transition from the G1 to S phase and the passage through the S phase [22, 23] . In its hypophosphorylated form, pRb is bound to E2Fs, thus preventing them from activating the target genes of the latter [24, 25] . In its hyperphosphorylated form, pRb dissociates from E2Fs, leaving them free to activate the target genes. Phosphorylation of pRb is induced by the cyclin Dcyclin-dependent protein kinase (CDK)-4 and -6 complexes and by cyclin E-CDK-2 complexes. The activities of CDKs are constrained by CDK inhibitors such as p16INK4a [26] . Many human cancers are characterized by RB1 mutation or deletion, INK4a mutation, deletion or gene silencing and cyclin D1 or CDK4 overexpression [27] . These alterations cause either RB1 loss or pRb hyperphosphorylation, thus inactivating the major control mechanism of cell cycle progression. Despite the fact that cancers harboring alterations in the RB pathway are generally more aggressive than those with a normal RB function [28] , the functional loss of pRb has been shown to increase cell sensitivity to both DNA-damaging agents and to drugs targeting the thymidylate biosynthesis pathway, such as 5-FU and MTX [reviewed in 29] . It is very likely that the greater sensitivity of pRb-deficient cancer cells to these drugs is due to the contemporary absence of a functioning cell cycle checkpoint and DNA repair mechanisms which protect cells from death by allowing time to repair the drug-induced DNA damage [8, [30] [31] [32] [33] . In agreement with these results, we have recently shown that patients with breast tumors characterized by the absence of pRb expression, who received systemic chemotherapy, had a better DFS than those whose cancers showed pRb positivity. This was independent of the cancer subtype. The absence of pRb expression appeared to be the only predictive factor of good clinical outcome in patients treated with adjuvant chemotherapy [8] . These clinical data therefore suggest that breast cancers lacking pRb are more sensitive to drugs used in chemotherapy treatment than those expressing the tumor suppressor. Evidence to support the importance of pRb in determining the response to chemotherapy agents was given by the observation that the high expression of three RB pathway gene signatures (RB1-LOH, RB-loss and proliferation signature), which are characterized by the common alteration of the RB1-E2F pathway, was associated with a complete pathological response in breast cancers treated with preoperative chemotherapy [34] . Interestingly, the same study showed that these RB pathway gene signatures were highly expressed in basal-like tumors, a tumor subtype which includes the majority of triple-negative cancers [7, 35, 36] . The results in the literature, together with our results, indicate that RB plays a key role in determining the response of TNBC to chemotherapy agents and, ultimately, in patients' clinical outcome. At a mean follow-up time of 109 months, all the patients with triple-negative cancer treated with adjuvant chemotherapy were disease free, whereas those with cancer characterized by pRb expression did not appear to benefit from chemotherapy. Indeed, the DFS did not differ from other subtypes of cancer. In our series of triple-negative cancers, the major change in the RB pathway was the loss of pRb expression, even though the percentage of cancers with pRb hyperphosphorylation was also greater than that of other types of tumors. The small number of cases of triple-negative tumors with hyperphosphorylated pRb treated with chemotherapy did not permit any statistical evaluation regarding the prognostic impact of inactivated RB in chemotherapy-treated patients. On the other hand, in a previous study, we did not find a significant prognostic value of pRb hyperphosphorylation in breast cancers treated with adjuvant chemotherapy [8] , thus suggesting that pRb loss, and not a simple loss of RB function, was responsible for the increased sensitivity of triple negative tumors to chemotherapeutic treatments.
conclusions
There is increasing evidence that the loss of RB function is associated with a differential response to wide-ranging therapeutic agents and that the status of this tumor suppressor could be especially informative in directing tumor treatments [29] . In the present study, we found that lack of pRb expression was more frequent in TNBCs than in the other cancer subtypes, and patients with triple-negative tumors lacking pRb had a very references
